FlashFeed

A new study published in JAMA Psychiatry finds that methylphenidate, a common ADHD medication, does not increase the risk of psychosis in children with attention deficit hyperactivity disorder. The findings contradict earlier concerns about the drug's psychiatric side effects. The results are considered significant for parents and physicians managing ADHD pharmacotherapy.

Wbrew wcześniejszym obawom, metylfenidat nie zwiększa ryzyka rozwoju psychozy u dzieci z zespołem nadpobudliwości psychoruchowej z deficytem uwagi (ADHD) – wynika z nowego badania, opublikowanego w „JAMA Psychiatry”.